CN101007167A - Mucosal meningococcal multivalence combined vaccines - Google Patents
Mucosal meningococcal multivalence combined vaccines Download PDFInfo
- Publication number
- CN101007167A CN101007167A CN 200710007045 CN200710007045A CN101007167A CN 101007167 A CN101007167 A CN 101007167A CN 200710007045 CN200710007045 CN 200710007045 CN 200710007045 A CN200710007045 A CN 200710007045A CN 101007167 A CN101007167 A CN 101007167A
- Authority
- CN
- China
- Prior art keywords
- group
- polysaccharide
- omp
- meningitis cocci
- combined vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 156
- 150000004676 glycans Chemical class 0.000 claims abstract description 197
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 196
- 239000005017 polysaccharide Substances 0.000 claims abstract description 196
- 101710116435 Outer membrane protein Proteins 0.000 claims abstract description 142
- 201000009906 Meningitis Diseases 0.000 claims abstract description 96
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 52
- 238000002360 preparation method Methods 0.000 claims description 55
- 238000010168 coupling process Methods 0.000 claims description 52
- 230000008878 coupling Effects 0.000 claims description 50
- 238000005859 coupling reaction Methods 0.000 claims description 50
- 239000002671 adjuvant Substances 0.000 claims description 30
- 239000000427 antigen Substances 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 239000002131 composite material Substances 0.000 claims description 18
- 239000003085 diluting agent Substances 0.000 claims description 17
- 229960000814 tetanus toxoid Drugs 0.000 claims description 17
- 230000001580 bacterial effect Effects 0.000 claims description 16
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 11
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 9
- 230000000890 antigenic effect Effects 0.000 claims description 5
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 5
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 3
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 2
- 208000034762 Meningococcal Infections Diseases 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 241001478240 Coccus Species 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 238000000034 method Methods 0.000 description 32
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 26
- 206010052369 Encephalitis lethargica Diseases 0.000 description 26
- 201000002498 viral encephalitis Diseases 0.000 description 26
- 239000000243 solution Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 13
- 239000008101 lactose Substances 0.000 description 13
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 12
- 229910052782 aluminium Inorganic materials 0.000 description 12
- 230000005847 immunogenicity Effects 0.000 description 11
- 229940031937 polysaccharide vaccine Drugs 0.000 description 10
- 241000894007 species Species 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- 239000004411 aluminium Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 230000036512 infertility Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241001597008 Nomeidae Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011046 pyrogen test Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010060123 Conjugate Vaccines Proteins 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229940031670 conjugate vaccine Drugs 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000007159 enucleation Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229940023143 protein vaccine Drugs 0.000 description 3
- 239000008174 sterile solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical group [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 108010012253 E coli heat-labile enterotoxin Proteins 0.000 description 1
- 206010014965 Ependymitis Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000008623 Subdural Effusion Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000005560 droplet transmission Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- CKGGRNFDFWFZDN-UHFFFAOYSA-L lithium;sodium;acetate;chloride Chemical compound [Li+].[Na+].[Cl-].CC([O-])=O CKGGRNFDFWFZDN-UHFFFAOYSA-L 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- -1 sodium chloride aluminum salt Chemical compound 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
The combined vaccine kind | Immunizing dose polysaccharide/albumen μ g | Anti-A group's polysaccharide | Anti-C group's polysaccharide | Anti-W135 group's polysaccharide | Anti-Y group's polysaccharide | Anti-B (4) group OMP | |||||
14 days | 28 days | 14 days | 28 days | 14 days | 28 days | 14 days | 28 days | 14 days | 28 days | ||
4 valency coupling polysaccharide+unit price BOMP | 1.25/3.75 | 18.9 | 39.6 | 19.0 | 56.7 | 17.2 | 73.8 | 23.3 | 103.9 | 134.3 | 658.6 |
4 valency coupling polysaccharide+unit price BOMP | 2.5/7.5 | 32.6 | 132.1 | 21.5 | 173.0 | 31.6 | 156.3 | 30.4 | 156.4 | 267.2 | 1632.3 |
4 valency coupling polysaccharide+unit price BOMP | 5.0/15.0 | 43.8 | 253.3 | 37.5 | 198.1 | 42.3 | 244.3 | 41.2 | 233.2 | 532.1 | 3210.6 |
4 valencys polysaccharide+unit price BOMP | 7.5/3.75 | 3.9 | 13.3 | 4.8 | 9.5 | 9.6 | 13.6 | 7.7 | 18.4 | 472.8 | 2533.7 |
4 valencys polysaccharide+unit price BOMP | 12.5/7.5 | 5.0 | 21.4 | 6.3 | 18.0 | 11.2 | 21.1 | 9.2 | 20.1 | 631.3 | 2715.4 |
4 valencys polysaccharide+unit price BOMP | 20.0/15.0 | 10.2 | 22.5 | 7.5 | 20.3 | 12.1 | 17.6 | 11.2 | 22.5 | 665.6 | 2635.3 |
The combined vaccine kind | The OMP source | Anti-A group's polysaccharide | Anti-C group's polysaccharide | Anti-W135 group's polysaccharide | Anti-Y group's polysaccharide | Anti-B (4) group OMP | Anti-B (15) group OMP | ||||||
14 days | 28 days | 14 days | 28 days | 14 days | 28 days | 14 days | 28 days | 14 days | 28 days | 14 days | 28 days | ||
4 valency coupling polysaccharide+divalent BOMP | B4/15 | 32.6 | 132.1 | 21.5 | 173.0 | 31.6 | 156.3 | 30.4 | 156.4 | 831.7 | 3278.2 | 975.5 | 4132.5 |
Divalent coupling polysaccharide+divalent BOMP | B4/15 | 43.2 | 175.3 | 23.3 | 153.9 | 659.5 | 2513.5 | 1130.0 | 3675.3 | ||||
Divalent coupling polysaccharide+unit price BOMP | B15 | 34.5 | 153.1 | 37.6 | 213.5 | 321.7 | 613.3 | 1035.2 | 3984.2 | ||||
4 valency coupling polysaccharide+unit price BOMP | B4 | 41.6 | 232.5 | 30.2 | 198.5 | 25.0 | 178.4 | 32.3 | 205.8 | 931.3 | 3521.2 | 423.3 | 635.0 |
4 valencys polysaccharide+divalent BOMP | B4/15 | 3.3 | 12.1 | 7.2 | 13.1 | 6.4 | 21.3 | 7.5 | 19.1 | 732.4 | 2138.4 | 763.3 | 3133.3 |
Divalent polysaccharide+divalent BOMP | B4/15 | 6.4 | 18.3 | 8.6 | 15.3 | 811.1 | 2556.3 | 803.1 | 3452.1 | ||||
Divalent polysaccharide+unit price BOMP | B15 | 4.6 | 13.5 | 7.1 | 19.5 | 235.5 | 563.6 | 821.0 | 3422.4 | ||||
4 valencys polysaccharide+unit price BOMP | B4 | 10.1 | 21.0 | 7.4 | 22.5 | 9.8 | 18.9 | 8.9 | 18.0 | 635.5 | 3812.5 | 222.4 | 513.3 |
The combined vaccine kind | The adjuvant kind | Anti-A group's polysaccharide | Anti-C group's polysaccharide | Anti-W135 group's polysaccharide | Anti-Y group's polysaccharide | Anti-B (4) group OMP | Anti-B (15) group OMP | ||||||
14 days | 28 days | 14 days | 28 days | 14 days | 28 days | 14 days | 28 days | 14 days | 28 days | 14 days | 28 days | ||
4 valency coupling polysaccharide ++ divalent BOMP | No adjuvant | 32.6 | 132.1 | 21.5 | 173.0 | 31.6 | 156.3 | 30.4 | 156.4 | 656.3 | 2436.0 | 738.6 | 3215.7 |
4 valency coupling polysaccharide ++ divalent BOMP | Aluminium hydroxide | 21.4 | 98.7 | 23.1 | 182.4 | 22.1 | 145.3 | 32.4 | 203.8 | 715.8 | 2135.4 | 739.0 | 3011.2 |
4 valency coupling polysaccharide ++ divalent BOMP | Aluminum phosphate | 27.3 | 132.5 | 25.2 | 136.5 | 19.4 | 163.3 | 31.5 | 194.0 | 686.1 | 1895.5 | 639.2 | 2856.4 |
4 valency coupling polysaccharide §+ divalent BOMP | No adjuvant diluent | 40.5 | 193.8 | 32.2 | 189.5 | 37.2 | 203.5 | 42.4 | 203.6 | 1350.3 | 3055.6 | 933.1 | 3451.9 |
4 valency coupling polysaccharide §+ divalent BOMP | The aluminium hydroxide dilution | 37.5 | 121.3 | 31.4 | 203.5 | 35.6 | 198.4 | 33.7 | 235.2 | 1213.4 | 3146.8 | 1315.0 | 2735.1 |
4 valency coupling polysaccharide § | Contain aluminum OMP diluent | 32.9 | 189.6 | 37.5 | 176.5 | 36.5 | 210.1 | 30.3 | 187.5 | 891.7 | 2733.1 | 1013.5 | 2913.3 |
The diluent kind | Anti-A group's polysaccharide | Anti-C group's polysaccharide | Anti-W135 group's polysaccharide | Anti-Y group's polysaccharide | Anti-B (4) group OMP | ||||||||||||||||||||
2 weeks | 8 weeks | 16 weeks | 32 weeks | 48 weeks | 2 weeks | 8 weeks | 16 weeks | 32 weeks | 48 weeks | 2 weeks | 8 weeks | 16 weeks | 32 weeks | 48 weeks | 2 weeks | 8 weeks | 16 weeks | 32 weeks | 48 weeks | 2 weeks | 8 weeks | 16 weeks | 32 weeks | 48 weeks | |
PBS | 16.3 | 102.5 | 203.4 | 175.6 | 82.3 | 19.2 | 205.4 | 236.2 | 163.5 | 54.3 | 21.4 | 136.8 | 2059 | 142.3 | 71.2 | 31.3 | 198.5 | 233.4 | 215.6 | 101.3 | 75.9 | 1231.3 | 2221.5 | 1835.6 | 1355.4 |
Aluminium hydroxide | 7.9 | 31.5 | 356.2 | 1384.5 | 2133.3 | 10.3 | 52.3 | 431.2 | 2311.5 | 2356.1 | 11.2 | 38.5 | 457.2 | 1668.0 | 2031.3 | 7.3 | 45.2 | 325.4 | 2138.3 | 1983.5 | 21.3 | 493.5 | 321.5 | 3232.5 | 2893.8 |
Aluminum phosphate | 8.3 | 54.3 | 415.5 | 1616.6 | 1938.4 | 9.5 | 63.1 | 325.3 | 2551.3 | 2711.5 | 9.3 | 41.6 | 572.3 | 2875.2 | 2213.4 | 9.5 | 50.5 | 431.4 | 2232.4 | 2512.3 | 18.5 | 325.8 | 532.3 | 2935.4 | 3245.3 |
Aluminum sulfate | 10.6 | 44.3 | 431.6 | 1523.1 | 2432.5 | 11.2 | 50.5 | 315.4 | 1935.8 | 2346.6 | 9.0 | 55.2 | 505.4 | 1893.2 | 2011.3 | 10.8 | 60.3 | 450.2 | 2012.2 | 2123.5 | 15.3 | 415.3 | 1275.4 | 3102.6 | 3315.2 |
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007100070451A CN100462102C (en) | 2007-02-07 | 2007-02-07 | Mucosal meningococcal multivalence combined vaccines |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007100070451A CN100462102C (en) | 2007-02-07 | 2007-02-07 | Mucosal meningococcal multivalence combined vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101007167A true CN101007167A (en) | 2007-08-01 |
CN100462102C CN100462102C (en) | 2009-02-18 |
Family
ID=38695978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2007100070451A Active CN100462102C (en) | 2007-02-07 | 2007-02-07 | Mucosal meningococcal multivalence combined vaccines |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100462102C (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102078604A (en) * | 2010-12-31 | 2011-06-01 | 北京民海生物科技有限公司 | Meningococcus capsular polysaccharide polyvalent multivalent conjugate vaccine, preparation method and application thereof |
CN102809656A (en) * | 2012-08-26 | 2012-12-05 | 云南沃森生物技术股份有限公司 | Method for detecting content of each group of free polysaccharide in meningococcus polysaccharide conjugate vaccine finished product |
CN101559223B (en) * | 2008-04-18 | 2013-02-13 | 重庆智仁生物技术有限公司 | Idemic encephalitis diphtheria-pertussis-tetanus combined vaccine |
CN103550773A (en) * | 2013-09-22 | 2014-02-05 | 成都康华生物制品有限公司 | Multivalent combined vaccine |
CN104001166A (en) * | 2014-05-13 | 2014-08-27 | 北京祥瑞生物制品有限公司 | Group A, group B and group C meningococcus combined vaccine and preparation method thereof |
CN104080479A (en) * | 2011-11-07 | 2014-10-01 | 诺华股份有限公司 | Carrier molecule comprising a spr0096 and a spr2021 antigen |
CN104096226A (en) * | 2014-05-11 | 2014-10-15 | 江苏康泰生物医学技术有限公司 | Method for enhancing 4-valent epidemic meningococcal polysaccharide protein bonder immunogenicity |
CN104096227A (en) * | 2014-05-11 | 2014-10-15 | 江苏康泰生物医学技术有限公司 | Method for enhancing 4-valent epidemic meningococcal polysaccharide protein bonder immunogenicity |
CN104127869A (en) * | 2014-07-18 | 2014-11-05 | 北京祥瑞生物制品有限公司 | Multivalent group B meningococcal protein vaccine and preparation method thereof |
CN104998255A (en) * | 2015-06-30 | 2015-10-28 | 北京祥瑞生物制品有限公司 | Novel ACYW135 meningococcal conjugate vaccine and preparation method thereof |
WO2017036139A1 (en) * | 2015-08-31 | 2017-03-09 | 成都欧林生物科技股份有限公司 | Preparation process for a-group neisseria meningitidis bacterium capsule crude polysaccharide |
CN109943536A (en) * | 2019-03-26 | 2019-06-28 | 昆明理工大学 | A kind of Hepatitis E virus, the preparation method of cultural method and its inactivated vaccine |
CN111281972A (en) * | 2020-03-24 | 2020-06-16 | 北京成大天和生物科技有限公司 | Combined vaccine consisting of ABCYW135 group meningococcus vaccine and encephalitis B vaccine |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083652B (en) * | 2013-02-06 | 2016-08-10 | 中国科学院过程工程研究所 | A kind of meningococcal polysaccharides combined vaccine with Heterobifunctional reagents as cross structure and preparation method thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0323102D0 (en) * | 2003-10-02 | 2003-11-05 | Chiron Srl | Liquid vaccines for multiple meningococcal serogroups |
-
2007
- 2007-02-07 CN CNB2007100070451A patent/CN100462102C/en active Active
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101559223B (en) * | 2008-04-18 | 2013-02-13 | 重庆智仁生物技术有限公司 | Idemic encephalitis diphtheria-pertussis-tetanus combined vaccine |
CN102078604A (en) * | 2010-12-31 | 2011-06-01 | 北京民海生物科技有限公司 | Meningococcus capsular polysaccharide polyvalent multivalent conjugate vaccine, preparation method and application thereof |
CN104080479A (en) * | 2011-11-07 | 2014-10-01 | 诺华股份有限公司 | Carrier molecule comprising a spr0096 and a spr2021 antigen |
CN104080479B (en) * | 2011-11-07 | 2019-11-05 | 葛兰素史密丝克莱恩生物有限公司 | Carrier molecules including spr0096 and spr2021 antigen |
CN102809656A (en) * | 2012-08-26 | 2012-12-05 | 云南沃森生物技术股份有限公司 | Method for detecting content of each group of free polysaccharide in meningococcus polysaccharide conjugate vaccine finished product |
CN103550773B (en) * | 2013-09-22 | 2015-04-08 | 成都康华生物制品有限公司 | Multivalent combined vaccine |
CN103550773A (en) * | 2013-09-22 | 2014-02-05 | 成都康华生物制品有限公司 | Multivalent combined vaccine |
CN104096226A (en) * | 2014-05-11 | 2014-10-15 | 江苏康泰生物医学技术有限公司 | Method for enhancing 4-valent epidemic meningococcal polysaccharide protein bonder immunogenicity |
CN104096227A (en) * | 2014-05-11 | 2014-10-15 | 江苏康泰生物医学技术有限公司 | Method for enhancing 4-valent epidemic meningococcal polysaccharide protein bonder immunogenicity |
CN104096226B (en) * | 2014-05-11 | 2020-06-19 | 江苏康泰生物医学技术有限公司 | Method for enhancing immunogenicity of 4-valent epidemic meningococcal polysaccharide protein conjugate |
CN104096227B (en) * | 2014-05-11 | 2020-06-19 | 江苏康泰生物医学技术有限公司 | Method for enhancing immunogenicity of 4-valent epidemic meningococcal polysaccharide protein conjugate |
CN104001166B (en) * | 2014-05-13 | 2018-03-09 | 北京祥瑞生物制品有限公司 | ABC group meningitis cocci combined vaccines and preparation method thereof |
CN104001166A (en) * | 2014-05-13 | 2014-08-27 | 北京祥瑞生物制品有限公司 | Group A, group B and group C meningococcus combined vaccine and preparation method thereof |
CN104127869B (en) * | 2014-07-18 | 2015-10-14 | 北京祥瑞生物制品有限公司 | Multivalence B group meningitis cocci protein vaccine and preparation method thereof |
CN104127869A (en) * | 2014-07-18 | 2014-11-05 | 北京祥瑞生物制品有限公司 | Multivalent group B meningococcal protein vaccine and preparation method thereof |
CN104998255B (en) * | 2015-06-30 | 2018-08-28 | 北京祥瑞生物制品有限公司 | New A CYW135 group meningitis cocci combined vaccines and preparation method thereof |
CN104998255A (en) * | 2015-06-30 | 2015-10-28 | 北京祥瑞生物制品有限公司 | Novel ACYW135 meningococcal conjugate vaccine and preparation method thereof |
WO2017036139A1 (en) * | 2015-08-31 | 2017-03-09 | 成都欧林生物科技股份有限公司 | Preparation process for a-group neisseria meningitidis bacterium capsule crude polysaccharide |
CN109943536A (en) * | 2019-03-26 | 2019-06-28 | 昆明理工大学 | A kind of Hepatitis E virus, the preparation method of cultural method and its inactivated vaccine |
CN109943536B (en) * | 2019-03-26 | 2021-09-14 | 昆明理工大学 | Method for culturing hepatitis E virus and method for preparing inactivated vaccine thereof |
CN111281972A (en) * | 2020-03-24 | 2020-06-16 | 北京成大天和生物科技有限公司 | Combined vaccine consisting of ABCYW135 group meningococcus vaccine and encephalitis B vaccine |
Also Published As
Publication number | Publication date |
---|---|
CN100462102C (en) | 2009-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100462102C (en) | Mucosal meningococcal multivalence combined vaccines | |
CN103533954B (en) | Contain compared with the antigen of low dosage and/or the combined vaccine of adjuvant | |
CN101951949B (en) | Meningococcal vaccine formulations | |
CN103656632B (en) | Multivalent pneumococcal capsular polysaccharide composition, its preparation method and application | |
CN103656631B (en) | multivalent pneumococcal capsular polysaccharide-protein conjugate composition and preparation method thereof | |
KR101588939B1 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
CN101785857B (en) | Novel pneumococcal conjugate vaccine and preparation method thereof | |
CN102596239A (en) | Immunogenic composition comprising antigenic S. aureus proteins | |
US20100291138A1 (en) | Vaccine | |
WO1996021465A2 (en) | Immunogenic conjugate molecules | |
CN1449293A (en) | Multivalent vaccine composition | |
CN102802662A (en) | Adjuvanted vaccines for serogroup B meningococcus | |
JP2018002743A (en) | Immunogenic compositions | |
US10046042B2 (en) | Meningococcal conjugate vaccine for groups A, C, Y and W135 and a preparation method thereof | |
CN103623401A (en) | Multivalent pneumococcus capsular polysaccharide-protein conjugated composition and preparation method thereof | |
CN102935226B (en) | Typhoid fever and paratyphoid fever combined vaccine and preparation method thereof | |
CN105517567A (en) | Immunogenic composition for use in therapy | |
CN101912609B (en) | Composition for preventing and controlling pseudomonas aeruginosa infection and preparation method thereof | |
CN107151270B (en) | Recombinate Δ fHbp-NadA fusion protein carriers and its preparation method and application | |
CN104383531A (en) | Combined vaccine for preventing meningitis in children and preparation method of combined vaccine | |
CN101559222A (en) | Combined vaccine bonding bacterial polysaccharides and protein for human | |
CN110251667A (en) | A kind of immune combination preparation and its preparation method and application | |
CN1209163C (en) | Meningococcal vaccine and its preparing method | |
CN106109486A (en) | A kind of compositions and preparation method and application | |
CN101130071A (en) | Vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: LONGKEMA PHARMACEUTICAL CO., LTD., ANHUI PROV. CHO Effective date: 20130217 Owner name: BEIJING LUZHOU BIOLOGICAL PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHONGQING ZHIREN BIOTECH COMPANY LTD. Effective date: 20130217 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 400020 JIANGBEI, CHONGQING TO: 100176 DAXING, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130217 Address after: 100176 No. 22 Tongji North Road, Beijing economic and Technological Development Zone Patentee after: Beijing Luzhou Biological Pharmaceutical Co., Ltd. Patentee after: Longkema Pharmaceutical Co., Ltd., Anhui Prov. Patentee after: Chongqing Zhiren Biotech Company Ltd. Address before: 400020, 25 floor, apartment B, Jin Yuan Times Square, 368 north shore road, Jiangbei District, Chongqing Patentee before: Chongqing Zhiren Biotech Company Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: BEIJING ZHIFEI LVZHU BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: BEIJING LUZHOU BIOLOGICAL PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 100176 No. 22 Tongji North Road, Beijing economic and Technological Development Zone Patentee after: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. Patentee after: Anhui Chi dragon coma biological pharmaceutical limited liability company Patentee after: Chongqing Zhiren Biotech Company Ltd. Address before: 100176 No. 22 Tongji North Road, Beijing economic and Technological Development Zone Patentee before: Beijing Luzhou Biological Pharmaceutical Co., Ltd. Patentee before: Longkema Pharmaceutical Co., Ltd., Anhui Prov. Patentee before: Chongqing Zhiren Biotech Company Ltd. |